Place of Origin: | China |
---|---|
Brand Name: | Senwayer |
Certification: | ISO, 9001, USP |
Model Number: | 84449-90-1 |
Minimum Order Quantity: | 10grams |
Price: | Discount is possible if your order is big enough |
Packaging Details: | 10g, 20g, 50g , 100g, 500g. 1kg, 10kg |
Delivery Time: | within 2 working days |
Payment Terms: | T/T in advance, Money Gram, Western Union, Bank Transfer. |
Supply Ability: | 1000kg/month |
CAS: | 84449-90-1 | Apparence: | Light Yellow Powder |
---|---|---|---|
Purity: | 99% | Storage: | Shading, Confined Preservation |
Usage: | Cancer Treatment Steroids | Stock: | Enough Stock |
High Light: | natural anti estrogen supplements,estrogen blocker supplement |
Medical Raloxifene 84449-90-1 Female Anti Estrogen And Cancer Treatment Steroids
Quick detail
Name: Raloxifene
CAS No.: 84449-90-1
Formula: C28H27NO4S
Molecular Weight: 473.58
Synonyms: Keoxifene;LY 139481;[2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone;
Density: 1.289 g/cm3
Melting Point: 250-253 °C
Boiling Point: 728.2 °C at 760 mmHg
Flash Point: 394.2 °C
Solubility: DMSO: 28 mg/mL, soluble
Appearance: light-yellow solid
Product Categories: Raloxifene;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate
Usage : A nonsteroidal estrogen receptor mixed agonist/antagonist
Raloxifene Description
Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium.
This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral density (BMD), and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral fractures in patients with previous, severe vertebral fractures.
Moreover, raloxifene appears to lower the risk of invasive breast cancer. Raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis.
We can therefore conclude that raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis, while reducing the risk of breast cancer when used at the indicated dose of 60 mg/day and with a low incidence of side effects.
Before taking raloxifene,
Certificate of Analysis
ITEMS | SPECIFICATION | RESULT | |
Appearance | White &off-white powder | Conforms | |
Grade | Anti Estrogen Steroids | Conforms | |
Solubility | Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water | Conforms | |
Identifications | Infrared Absorption | Conforms | |
Loss on drying | ≤0.5% | 0.4% | |
Residue on ignition | ≤0.1% | 0.06% | |
Heavy metals | ≤10ppm | Conforms | |
Raloxifene Impurity1 | ≤0.20 % | 0.10% | |
Any unspecified individual impurity 2 | ≤0.10% | Max. 0.08% | |
Total impurities | ≤0.50% | 0.40% | |
Raloxifene | ≥98.0% | 99.0% |